Suppr超能文献

CFAR 网络整合临床系统队列中的传播性耐药:流行率及其对治疗前 CD4 和病毒载量的影响。

Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load.

机构信息

BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

出版信息

PLoS One. 2011;6(6):e21189. doi: 10.1371/journal.pone.0021189. Epub 2011 Jun 20.

Abstract

Human immunodeficiency virus type 1 (HIV-1) genomes often carry one or more mutations associated with drug resistance upon transmission into a therapy-naïve individual. We assessed the prevalence and clinical significance of transmitted drug resistance (TDR) in chronically-infected therapy-naïve patients enrolled in a multi-center cohort in North America. Pre-therapy clinical significance was quantified by plasma viral load (pVL) and CD4+ cell count (CD4) at baseline. Naïve bulk sequences of HIV-1 protease and reverse transcriptase (RT) were screened for resistance mutations as defined by the World Health Organization surveillance list. The overall prevalence of TDR was 14.2%. We used a Bayesian network to identify co-transmission of TDR mutations in clusters associated with specific drugs or drug classes. Aggregate effects of mutations by drug class were estimated by fitting linear models of pVL and CD4 on weighted sums over TDR mutations according to the Stanford HIV Database algorithm. Transmitted resistance to both classes of reverse transcriptase inhibitors was significantly associated with lower CD4, but had opposing effects on pVL. In contrast, position-specific analyses of TDR mutations revealed substantial effects on CD4 and pVL at several residue positions that were being masked in the aggregate analyses, and significant interaction effects as well. Residue positions in RT with predominant effects on CD4 or pVL (D67 and M184) were re-evaluated in causal models using an inverse probability-weighting scheme to address the problem of confounding by other mutations and demographic or risk factors. We found that causal effect estimates of mutations M184V/I (-1.7 log₁₀pVL) and D67N/G (-2.1[³√CD4] and 0.4 log₁₀pVL) were compensated by K103N/S and K219Q/E/N/R. As TDR becomes an increasing dilemma in this modern era of highly-active antiretroviral therapy, these results have immediate significance for the clinical management of HIV-1 infections and our understanding of the ongoing adaptation of HIV-1 to human populations.

摘要

人类免疫缺陷病毒 1 型(HIV-1)基因组在传播给未经治疗的个体时,通常会携带一个或多个与耐药性相关的突变。我们评估了在北美的一个多中心队列中,慢性感染未经治疗的患者中传播的耐药性(TDR)的流行率和临床意义。治疗前的临床意义通过基线时的血浆病毒载量(pVL)和 CD4+细胞计数(CD4)来量化。用世界卫生组织监测清单定义的耐药突变对 HIV-1 蛋白酶和逆转录酶(RT)的原始群体序列进行筛选。TDR 的总体流行率为 14.2%。我们使用贝叶斯网络来识别与特定药物或药物类别相关的耐药突变簇的共同传播。根据斯坦福 HIV 数据库算法,通过对根据 TDR 突变加权求和的线性模型拟合,估计药物类别中突变的聚合效应。对两类逆转录酶抑制剂的传播耐药性与 CD4 降低显著相关,但对 pVL 的影响相反。相比之下,TDR 突变的位置特异性分析显示,在几个残基位置对 CD4 和 pVL 有实质性影响,这些影响在总体分析中被掩盖了,并且存在显著的相互作用效应。对 CD4 或 pVL 有主要影响的 RT 残基位置(D67 和 M184)在因果模型中使用逆概率加权方案进行了重新评估,以解决由其他突变和人口统计学或风险因素引起的混杂问题。我们发现突变 M184V/I(-1.7log₁₀pVL)和 D67N/G(-2.1[³√CD4]和 0.4log₁₀pVL)的因果效应估计值被 K103N/S 和 K219Q/E/N/R 补偿。随着 TDR 在现代高效抗逆转录病毒治疗时代成为一个越来越大的困境,这些结果对 HIV-1 感染的临床管理以及我们对 HIV-1 对人类群体的持续适应的理解具有直接意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69e8/3118815/9fc7d7f5e939/pone.0021189.g001.jpg

相似文献

5
Community HIV-1 drug resistance is associated with transmitted drug resistance.
HIV Med. 2014 Jul;15(6):339-46. doi: 10.1111/hiv.12122. Epub 2014 Jan 12.
6
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016.
HIV Med. 2018 Oct;19(9):619-628. doi: 10.1111/hiv.12640. Epub 2018 Jun 22.
7
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.
AIDS. 2010 Jul 31;24(12):1917-22. doi: 10.1097/QAD.0b013e32833c1d93.
8
Prevalence and patterns of HIV transmitted drug resistance in Guatemala.
Rev Panam Salud Publica. 2011 Dec;30(6):641-8. doi: 10.1590/s1020-49892011001200024.
9
Prevalence of transmitted HIV-1 drug resistance among treatment-naive individuals in China, 2000-2016.
Arch Virol. 2021 Sep;166(9):2451-2460. doi: 10.1007/s00705-021-05140-9. Epub 2021 Jun 30.

引用本文的文献

2
Ethical issues in HIV phylogenetics and molecular epidemiology.
Curr Opin HIV AIDS. 2019 May;14(3):221-226. doi: 10.1097/COH.0000000000000538.
3
Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa.
AIDS Res Hum Retroviruses. 2019 Feb;35(2):129-138. doi: 10.1089/AID.2018.0202. Epub 2019 Jan 7.
7
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.
J Int AIDS Soc. 2016 Oct 23;19(8(Suppl 7)):21487. doi: 10.7448/IAS.19.8.21487. eCollection 2016.
9
IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform.
PLoS Comput Biol. 2014 Sep 25;10(9):e1003842. doi: 10.1371/journal.pcbi.1003842. eCollection 2014 Sep.

本文引用的文献

2
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.
AIDS. 2010 Jul 31;24(12):1917-22. doi: 10.1097/QAD.0b013e32833c1d93.
6
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.
PLoS One. 2009;4(3):e4724. doi: 10.1371/journal.pone.0004724. Epub 2009 Mar 6.
9
When to start antiretroviral therapy?
Clin Infect Dis. 2008 Dec 15;47(12):1580-6. doi: 10.1086/593311.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验